Angiogenesis is a requirement for solid tumor growth. Therefore, inhibition of this neovascularization is one mechanism by which restoration of wtp53 function may lead to tumor regression. Here we report that adenoviral vector -mediated wild -type p53 transduction results in growth inhibition of squamous cell carcinoma of the head and neck tumor cells both in vitro and in a xenograft mouse model. This growth inhibition is associated with the down -regulation of the expression of fibroblast growth factor binding protein, a secreted protein required for the activation of angiogenic factor basic FGF. These findings suggest that wtp53 -induced tumor regression is due, at least in part, to antiangiogenesis mediated by the downmodulation of fibroblast growth factor binding protein. Cancer Gene Therapy ( 2001 ) 8, 771 -782 
A ngiogenesis is essential for the growth and metastasis of solid tumors. 1 It is controlled by the local balance between factors that stimulate and factors that inhibit this complex multistep process. 2 Additionally, preclinical gene therapy studies have indicated that adenoviral vector ( Adv )-mediated expression of antiangiogenic protein( s ) may represent an attractive therapeutic model for cancer and other angiogenesis-dependent diseases. 3 -5 For example, the extent of neovascularization in primary tumors has been shown to correlate with a negative prognosis in small cell lung carcinoma, prostate, and breast cancers. 6 A number of positive and negative cytokine mediators of tumor angiogenesis have been described, including transforming growth factor beta (TGF -), 7, 8 vascular endothelial growth factor (VEGF ), 9, 10 fibroblast growth factor ( FGF ), 11 interferon-, 3 and thrombospondin (TSP -1 ). 2 The tumor-suppressor gene p53 has been shown to transcriptionally regulate a number of factors, some of which are secreted proteins that either inhibit (e.g., glioblastoma-derived angiogenesis inhibiting factor ( GD -AIF ) and TSP -1) or promote (e.g., VEGF and FGF ) angiogenesis. 12 FGFs comprise a family of structurally related polypeptides. All members of this family bind strongly to heparin and share certain common structural characteristics. In addition to playing multifaceted roles in many developmental and regenerative processes, FGFs have also been shown to be regulators of cellular proliferation, migration, and differentiation in vitro, and are potent angiogenic factors in both blood vessel formation and wound repair in vivo.
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The most -studied members in man are FGF -1 and FGF -2 ( acidic and basic FGF, respectively ). Both are mitogenic to a wide variety of cells and their biological activities are mediated by binding to a family of protein tyrosine kinase cell surface receptors.
FGF -1 and FGF -2 (bFGF ) are expressed in several types of tumor cells, 16 -18 supporting malignant growth by stimulating blood vessel formation. 19, 20 FGF -1 and bFGF are also expressed in the extracellular matrix ( ECM ) of many normal cells. 21 -24 A novel pathway for bFGF mobilization from the ECM by binding to a secreted binding protein, bFGF -BP, has been proposed. 25 This protein of M r 17 kDa was found to bind to FGF -1 and bFGF in a noncovalent, reversible manner, and to stabilize their biological activity as well as prevent their inactivation. 26 Homologues of this protein have also been recently identified in mice, 19 rats, 27 and cows, 28 and contain 10 cysteine residues whose position is conserved across species. Human bFGF -BP is expressed in normal keratinocytes and in squamous cell carcinoma of the head and neck ( SCCHN ) -derived cell lines as well as in tumor tissues. 25, 26 Whereas little is known about the exact role of bFGF -BP in carcinogenesis, it has been suggested that bFGF -BP may function during development and in the early stages of carcinogenesis to activate bFGF. 19 The tumor-suppressor gene p53 is the most frequently mutated gene identified in human cancers and is also known to be a transcriptional regulator of a variety of genes. Restoration of wild -type (wt ) p53 function by means of a replication-defective Adv has been shown to inhibit tumor cell growth at a level far greater than might be expected based upon the limited transfection efficiency of adenovirus in vivo. 29, 30 Because it is unlikely that this therapeutic gene can be introduced into 100% of the tumor cell population, the successful eradication of tumors would depend on a phenomenon called the ''bystander effect,'' through which the introduced gene can affect cells distant from it. The thymidine kinase gene from the herpes simplex virus (HSV-TK ), in combination with the prodrug ganciclovir ( GCV ), has been used in some animal models and exhibits a strong bystander effect. A number of studies have found that in the HSV-TK /GCV system, HSV-TKpositive cells exposed to GCV were lethal to HSV-TKnegative cells both in vitro and in vivo. 31 -37 This effect was found even when HSV-TK -positive cells represented as few as 10% of the tumor cells. 31 Several mechanisms have been proposed to account for this observed effect including induction of apoptosis, 38, 39 the transfer of toxic metabolites through gap junctions, 40, 41 and cell -mediated antitumor toxicity. 42, 43 In contrast, the bystander effects in the context of p53 -mediated gene therapy are not well understood. However a few reports present some interesting possibilities. Waku et al 44 have reported that intratumoral inoculations with Advp53, which causes an overexpression of CD95 ligand (Fas ligand ), induced antitumor effect through neutrophil infiltration into human colorectal xenograft tumors. They suggested that this neutrophil accumulation was responsible for a bystander apoptotic effect in nontransduced tumor cells. 44 Nishizaki et al 45 also showed that recombinant Advp53 gene transfer into a mutant p53-expressing human nonsmall cell lung cancer cell line markedly inhibited the expression of an angiogenic factor, VEGF, and increased the expression of a novel antiangiogenic factor, brain -specific angiogenesis inhibitor 1 ( BAI -1 ), resulting in reduced tumor neovascularization in vivo. They attribute these results to a bystander effect leading to antiangiogenesis induced by the exogenous wtp53. In another study involving liposome as a gene delivery system, Xu et al 46 intravenously injected a liposome:p53 complex into nude mice, which resulted in a reduction in the number of blood vessels in human breast cancer xenografts by approximately 60%. The close correlation between the antitumor effect of p53 and the reduction of blood vessel density in the tumor suggested, at least in part, that p53 effects are mediated by an antiangiogenesis mechanism. 46 Although the above studies indicate that the introduction of an exogenous wtp53 gene into tumor cells may result in death of neighboring unmodified tumor cells through a bystander effect in vivo, a study by Frank et al 47 reported that the supernatant from Advp53-infected human SCCHN cells demonstrated no growth -inhibitory effect on nontransduced cells in vitro, suggesting that at least in this system, a bystander effect may require cellular contact. These findings suggest that p53, in addition to its intrinsic antiproliferative activity, can cause a bystander effect by inducing the export of growth -suppressive stimuli to neighboring cells, but that this effect may require interaction between the tumor cells and other tissue components. Thus, the term bystander effect may cover a variety of distinct mechanisms.
In the present study, we examined the ability of wtp53, introduced by means of an adenoviral construct, to modulate the expression of bFGF -BP in SCCHN in vitro and in vivo. Our results demonstrate that exogenous wtp53 downmodulates the expression of bFGF -BP in vitro and in a nude mouse xenograft model, resulting in tumor regression. These findings indicate that down -regulation of this secreted molecule potentially represents a crucial signal in a pathway leading to antiangiogenesis and tumor regression. Moreover, this downmodulation may play a role in a p53-mediated bystander effect.
MATERIALS AND METHODS

Cell culture and in vitro viral infection
Radiation -resistant SCCHN cell line JSQ -3 carries a mutant form of the p53 gene ( mtp53 ). 48 This cell line, which was derived from a recurrent tumor of the nasal vestibule post radiotherapy, 49 was a generous gift from Dr. Ralph Weichselbaum ( University of Chicago ). JSQ -3 cells were maintained in minimum essential medium with Earl's salts, supplemented with 10% heat -inactivated fetal bovine serum; 50 g /mL each of penicillin, streptomycin, and neomycin; 0.4 g /mL hydrocortisone; 2 mM L -glutamine; 0.1 mM nonessential amino acids; and 1 mM sodium pyruvate.
The replication -defective adenoviral constructs used in these studies were obtained from Dr. Yawen Chiang (then at GTI /NOVARTIS, Gaithersburg, MD ). The construction and purification of the control Adv carrying the -galactosidase gene (Av1LacZ4 ) under control of the RSV promoter have been previously described. 50 -52 An identical methodology was employed for the construction of an Adv carrying wtp53. 29 This adenoviral construct, designated in this report as Av1p53, contains a normal 1.3-kb human wtp53 cDNA in place of -galactosidase. 29 For in vitro viral infection, the cells, at approximately 30-50% confluence, were washed once with serum -free medium. The cells were then incubated at 378C with gentle rocking, with 30 multiplicity of infection ( MOI ) of either Av1p53 or Av1LacZ4, which had been diluted to the appropriate plaque -forming unit (pfu) concentration with phosphate -buffered saline (PBS ). At the end of 2 hours, fresh medium was added to the culture without removal of the virus.
Protein analysis
Cells for p53 protein analysis were infected with 30 MOI of Av1p53 as described above. At various times postinfection, the cells were trypsinized, pelleted, rinsed with PBS, and lysed in RIPA buffer (1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 30 g /mL aprotinin, and 1 mM sodium orthovanidate in PBS ) (Santa Cruz Biotechnology, Santa Cruz, CA ). After shearing with a 26 -gauge needle, 100 g/ mL phenylmethysulfonylfluoride was added, the lysate incubated on ice for 30-60 minutes and centrifuged at 13,000Âg for 20 minutes at 48C to pellet insoluble material. Protein concentration was determined using the micro-BCA Protein Assay Kit (Pierce Biochemical, Rockford, IL ). Forty micrograms of protein lysate was mixed with an equal volume of 2 protein sample buffer [ 0.05 M Tris ( pH 6.8), 3% SDS, 20% glycerol, 6% 2-mercaptoethanol, and 0.001% bromophenol blue ] boiled for 5 minutes, loaded on a 10% ( 4% stacking gel ) SDS / polyacrylamide gel, and electrophoresed at 200 V for 8 hours. The protein was transferred to nitrocellulose membrane as previously described. 53 Preparation of the membrane and incubation with the primary and secondary antibodies were performed essentially as described in a protocol supplied by Santa Cruz Biotechnology, with the exception that incubation with the primary antibody ( antip53 antibody Ab -2; Oncogene Research Products, Cambridge, MA ) was extended to 2 hours, with wash times of 15 minutes per wash. The washings after addition of the secondary antibody ( antimouse IgG -HRP; Santa Cruz Biotechnology) were also lengthened to 15 minutes per wash. Visualization of the protein was accomplished using the ECL Western Blotting Kit (Amersham, Piscataway, NJ ) according to the manufacturer's protocol.
RNA isolation
Total RNA was isolated from untreated Av1p53 or Av1Laz Z4 in vitro -infected cells at various times (2 -7 days ) postinfection using RNAzolB (Tel-Test, Friendswood, TX ) according to the manufacturer's protocol. For in vitro studies, the cells were trypsinized, pelleted, and washed once with PBS prior to lysis with RNAzolB. Mouse xenograft tumors were excised, cut into small pieces, and flash-frozen in liquid nitrogen. Homogenization of the frozen tissue in RNAzolB was performed on ice in a 1.5-mL RNAse-free microcentrifuge tube using a motorized pellet pestle homogenizer ( Kontes, Vineland, NJ ).
Northern analysis
A 20-g sample of total RNA was separated by electrophoresis on a 1.1% agarose gel containing formaldehyde ( final concentration 2.2 M), and transferred to nylon membrane. The membrane was hybridized with 32 P random prime labeled probes for p53, bFGF -BP [a polymerase chain reaction ( PCR ) -amplified product ], MDM-2, waf -1, bFGF, IGF -BP3 (a PCR -amplified product ), TSP -1 (a PCR -amplified product ), and human -actin.
Reverse transcription ( RT ) PCR
On the basis of published sequences for bFGF -BP 25 and IGF -BP3, 54 we prepared pairs of oligonucleotide primers for RT-PCR of these genes. RT-PCR of the human -actin gene was used as internal control. The primers employed were: bFGF -BP sense, 5
0 -GGAGGGGAAAAAAAAAGT-GAAG -3 0 and antisense, 5 0 -TTGGATTGCCAGCAAA-GAC -3 0 primers; IGF3 -BP sense, 5
0 -TCAGAGGCATCACAAG-TAATGG -3 0 and antisense, 5 0 -ACATGGGTGAATCTC-TATGTGC -3 0 primers; and human -actin sense, 5
0 -CCTTCCTGGGCATG-GAGTCCTG -3 0 and antisense, 5 0 -GGAGCAAT-GATCTTGATCTTC-3 0 primers.
The expected PCR product sizes from these three sets of primers are 239, 251, and 200 bp, respectively. cDNA was synthesized from 0.2 g of total RNA ( isolated as described above ) in a 25 L reaction mixture containing 0.2 mM of each dNTP (Pharmacia, Piscataway, NJ ), 10 mM DTT, and 0.5 g targetspecific antisense primer. After incubation at 708C for 10 minutes, followed by 10 minutes at 378C, 200 U MMLV reverse transcriptase (Life Technologies, Grand Island, NY ) was added, and the mixture incubated at 378C for 30 minutes, followed by inactivation of the enzyme by heating at 908C for 5 minutes. A negative control sample without RNA was included in each experiment.
Preliminary experiments were performed using untreated JSQ -3 cells to determine the number of cycles within which amplification of the bFGF -BP gene or the -actin gene, used as a control, would proceed exponentially. A 10 L sample of the PCR reaction was taken at two cycle increments from 12 to 28, subjected to electrophoresis, and hybridized with the probe for bFGF -BP or -actin. We found a linear increase in the amount of PCR product for both genes with cycles 16 through 22. In order to determine a semiquantitative difference in bFGF -BP expression by this method, an effort was made to equalize the samples based upon the level of the control -actin expression. The amount of control -actin cDNA in each sample was determined after the initial RT phase of the PCR reaction. Based upon the hybridization signal for -actin, the volume of the cDNA reaction mixture used in the second phase of the PCR reaction was adjusted to result in equivalent levels of -actin product for each sample. This is equivalent to equalizing the amount of RNA used in the reaction. The identical ratios, determined by this method to give equivalent levels of control -actin signals, were then used in a separate RT-PCR reaction to examine changes in bFGF -BP expression after Av1p53 or Av1Lac Z4 infection.
The appropriate amount of cDNA was amplified by PCR in a final volume of 100 L containing 0.5 g of the sense and 0.25 g of the antisense primers, 0.2 mM of each dNTP, and 4 U Taq Polymerase (Boehringer Mannheim Biochemical, Indianapolis, IN ). Each tube was overlaid with 20 L mineral oil. The amplification conditions for bFGF -BP and -actin were: an initial denaturation at 948C for 5 minutes, followed by 12-28 repeated cycles of denaturation at 948C for 30 seconds; annealing at 458C for 2 minutes, and extension 728C for 1 minute. The final amplification cycle was followed by a 5-minute extension reaction at 728C. After the initial denaturation step, the amplification conditions for IGF -BP3 were: 948C for 1 minute and 45 seconds; annealing at 568C for 2 minutes and extension at 728C for 3 minutes, for 14 -18 cycles. A negative control sample without cDNA was included in each experiment. Ten microliters of each final PCR product was subjected to electrophoresis on a 1.8% agarose gel, transferred to nylon membrane, and hybridized with the appropriate 32 P -labeled ( random prime ) probe. Densitometry was performed on a Howtek Scanner using PDI Discovery Series software at the Lombardi Cancer Center's Macromolecular Synthesis and Sequencing Shared Resource. 3 were evident at the injection sites, the animals were divided into groups. Each group was injected one time, directly into the right shoulder tumor only, with 2Â10 9 pfu of Av1p53 or Av1LacZ4 (in 50 L PBS ). Control tumors were injected with PBS. Two, 5, and 9 days postinjection, one animal from each group was sacrificed, and each of the two tumors excised from the animal, cut into pieces, flash -frozen, and used for RT-PCR and protein analysis.
RESULTS
We have previously shown that Adv -mediated restoration of wtp53 into SCCHN JSQ -3 cells was able to inhibit their growth in vitro and in vivo. 29 The tumor growth inhibition and cell death observed in vivo exceeded that which might be expected from the poor transduction efficiency associated with intratumoral infection, indicating that a wtp53-mediated bystander effect may be occurring. In this study, we wished to examine the relationship between Adv - 8 pfu ) of either Av1p53, which contains the complete open reading frame of human wtp53, or the control Av1LacZ4, which carries the -galactosidase gene in place of p53. Two, 4, and 7 days postinfection, the cells were collected and both protein and total RNA isolated. Western and Northern analyses were performed to examine the level of wtp53 protein and message being expressed in these infected cells. As shown in Figure 1 , the level of p53 protein increased with time in the Av1p53 -infected cells. Even 2 days after infection, there is a significant amount of exogenous wtp53 protein being produced in these cells, which is not evident in either the control or Av1LacZ4 -treated cells. Moreover, an increase is also observed in the endogenous mtp53 band with time. A similar observation was made by Liu et al 55 after treatment of two different SCCHN cell lines with a wtp53 adenoviral construct under control of the CMV promoter. Data indicate that, at least in murine cell lines, wild type, but not mutant, p53 is capable of transactivating its own promoter through a sequence nearly identical to the NF -B binding site. 56 This increase in endogenous p53 may therefore be attributable to this transcriptional autoregulation.
Down -regulation of bFGF -BP expression by
Adv -mediated restoration of wtp53 in vitro bFGF -BP, the binding protein for the angiogenic factor bFGF, has been shown to be elevated in squamous cell carcinoma cell lines and tumors. 25 bFGF -BP has been hypothesized to mobilize bFGF, an angiogenic factor down -regulated by p53. 12 bFGF -BP is a secreted protein, To examine the time course of the downmodulation of bFGF -BP, a 7-day daily sampling was performed. As shown in Figure 2 , the level of bFGF -BP message in the Av1p53 -infected cells dramatically decreased. Downmodulation of bFGF -BP was evident by day 3 and by day 4 the message was virtually undetectable. It should be noted that the amount of the RNA on day 3, based on the actin level, was higher than day 2. In contrast, no significant change in the Figure 6 . Downmodulation of bFGF -BP in distant noninjected tumors. Tumors which were not injected, but which had been induced on the same animal as those tumors injected with Av1p53 or Av1LacZ4, were also excised at 2, 5, and 9 days. A: The tumors were flash -frozen and RNA isolated using RNAzolB. RT -PCR was performed as in Figure 2A . B: Exogenous wtp53 protein expression in these second, uninjected tumors. UT: tumor from completely untreated mouse.
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Northern analysis confirmed this wtp53-specific downmodulation of bFGF -BP, with a concomitant time-dependent increase in p53 expression in the Av1p53-treated cells ( data not shown). As was observed by RT-PCR, no significant change in the expression of bFGF -BP was evident in either the untreated or the Av1LacZ4 -infected cells (data not shown). Other p53 response genes, including waf -1, MDM-2, the antimitogenic factor, insulin -like growth factor binding protein -3, IGF -BP3, 54 the antiangiogenic factor TSP -1, 57 as well as bFGF, were also examined for changes in their expression due to reintroduction of wtp53. No significant differences in the level of mRNA expression of IGF -BP3, TSP -1, or MDM -2 were found. A time -dependent increase in waf -1 expression, mirroring that seen for p53, was evident and, as with p53 expression, was observed only in the Av1p53 -infected cells. However, no significant change in the level of bFGF mRNAwas evident in response to wtp53 restoration in these cells (data not shown ).
Wtp53 downmodulation of bFGF -BP in xenografts
For regulation of bFGF -BP to be considered as a component of a wtp53 -mediated antitumor and/ or bystander effect, it is critical to determine if the downmodulation seen in in vitro experiments is also observed in vivo. Therefore, subcutaneous JSQ -3 nude mouse xenograft tumors of approximately 30 mm 3 were established. The tumors were intratumorally injected one time with 2Â10 9 pfu of Av1p53 or Av1LacZ4. Two, 5, and 9 days after injection, the tumors were excised and analyzed. It was noted that even over the very short term of this in vivo experiment, the Av1p53 -injected tumors regressed significantly (approximately 3-fold ) ( Fig 3 ) . A small decrease in tumor size was also noted in the Av1LacZ4-treated group.
Western analysis for the expression of the exogenous wtp53 protein in the tumors is shown in Figure 4 . Analogous to the in vitro study, high levels of wtp53 protein are clearly being expressed in the Av1p53 -treated tumors up to 9 days after a single virus injection, whereas the untreated and Av1LacZ4 controls display only the endogenous mtp53 protein. Due to the small size of the tumors, particularly in the Av1p53 -treated group, Northern analysis was prohibitive. Consequently, RT-PCR analysis was performed on the tumor RNA. Here also, the in vivo results mirror those of the in vitro study. bFGF -BP RNA expression is almost completely eliminated 2 days after Av1p53 injection ( Fig  5A ) , and virtually no signal is detectable at 5 and 9 days postinfection. As before, no change in bFGF -BP expression is found in the controls, demonstrating the wtp53 specificity of this response. Densitometric quantitation of this decrease is shown in Figure 5B .
Effect of Av1p53 treatment on distant tumors
In clinical trials involving head and neck cancers, it has been reported that Advp53 can be found in the sputum, urine, and blood of the patients 24-48 hours after direct intratumoral inoculations. 73 To determine what effect this disseminated virus might have on a tumor site distant from the inoculated tumor, in addition to the subcutaneous JSQ -3 xenograft tumor located on the upper right shoulder of the mouse, we also established a second xenograft tumor at a distant site on the mouse (on the lower left flank ). These tumors were distant enough from the injected tumor to most likely be free of any direct contact with the injected adenovirus. As shown in Figure 6A , a time -dependent decrease in the level of bFGF -BP expression was also evident in the distant tumors from the animals whose corresponding shoulder tumors had been injected with Av1p53, whereas those from the untreated or Av1LacZ4 animals showed no change in bFGF -BP expression. The timing of the decrease was shifted as compared to the directly injected tumor. bFGF -BP expression is greatly decreased at 2 days and almost completely eliminated by day 5 in the treated tumor ( Fig 5A ) . However, whereas a drop in bFGF -BP expression is evident at day 5 in the distant tumor, the message does not completely disappear until day 9 (Fig 6A ) . The timing of this decrease correlates with the increase in wtp53 protein levels evident in this tumor ( Fig 6B ) . These findings are also consistent with the inhibition of tumor growth, but not regression, observed in this distant tumor. These findings demonstrate that dissemination of even intratumorally injected Advp53 can likely have some beneficial effects on a distant tumor.
DISCUSSION
The tumor-suppressor gene p53 may inhibit tumor growth through the activation of apoptosis, inhibition of cell cycle progression, or the inhibition of angiogenesis. Direct induction of the apoptotic pathway or cell cycle arrest alone cannot account for the level of tumor cell death observed in various studies using wtp53 replacement gene therapy because this would require that 100% of the tumor cells be transfected. One mechanism by which restoration of wtp53 function may lead to tumor growth suppression and regression is inhibition of angiogenesis. Conversion to the angiogenic phenotype involves the concomitant downmodulation of endothelial inhibitors, such as TSP -1, and the up-regulation of angiogenic factors, such as bFGF and VEGF.
58 p53 has been shown to transcriptionally regulate many of these angiogenic and antiangiogenic factors. 12 In addition, Volpert et al 59 demonstrated that the development of the angiogenic phenotype in human fibroblasts occurs in a stepwise fashion and was dependent upon loss of both alleles of wtp53. Thus, restoration of wtp53 function in tumor cells could lead to inhibition of angiogenesis. For example, Adv -mediated transduction of colon cancer cells with wtp53 was shown by Bouvet et al 60 to decrease VEGF expression with a concomitant inhibition of tumor cellinduced angiogenesis in vivo. Furthermore, systemic cationic liposomal delivery of wtp53 to C57B16 mice carrying intravenously introduced B16 -F10 melanoma lung nodules resulted in reduced tumor angiogenesis and metastatic spread, as well as an increase in the production of TSP -1 in the tumor cells. 61 The role of bFGF in tumor growth and angiogenesis is supported by the fact that soluble bFGF has been found at elevated levels in the serum and urine of patients with a wide variety of cancers. 62 There is increasing evidence to support the theory that mobilization of bFGF from tissue stores within the ECM, rather than increased production, may be the source of this bFGF. 63, 64 Significantly, bFGF -BP has been shown to facilitate the mobilization of bFGF from the ECM. 25, 63 When an expression vector for bFGF -BP is transfected into a human cell line that is already producing constitutively high levels of bFGF, bFGF -BP -expressing cells begin to grow as colonies in soft agar due to autocrine stimulation by bFGF. These cells release biologically active bFGF into their media and cause vascularized tumors in athymic nude mice. 25 Epidermal growth factor has recently been shown to induce the transcription of bFGF -BP in vitro. 65 A significant up -regulation of FGF -BP during phorbol ester TPA (12 -Otetradecanoylphorbol -13 -acetate) promotion of skin cancer in mice has also been observed. Removal of bFGF -BP increases the cell -bound bFGF and simultaneously quenches the release into the medium of biologically active bFGF. Consequently, tumor growth and angiogenesis in vivo are reduced. 63, 66 The data presented here in our study show that Advmediated introduction of wtp53 into a human SCCHN cell line resulted in a time -dependent down -regulation of the expression of bFGF -BP. This downmodulation of bFGF -BP expression in vitro was evident by day 2. At day 4, the message was virtually undetectable. In contrast, no significant change was apparent in the RNA levels of MDM-2 (a protein that modulates p53 activity ), the antimitogenic factor IGF -BP3, ( an autocrine /growth regulator through its inhibition of the insulin growth factor pathway, which can be induced in cells after DNA damage, 54 ) or the antiangiogenic factor TSP -1. Both IGF -BP3 and TSP -1 have been implicated in the bystander effect in other systems. 67, 68 The finding here, that the expression of neither TSP -1 nor IGF -BP3 is significantly altered in Av1p53 -treated cells, is in contrast to previous observations. 45, 57, 61, 69 The discrepancy between these findings could be related to tissue specificity. We also noted that, similar to the results reported by Nishizaki et al 45 who used an Adv to transduce wtp53 into nonsmall cell lung cancer, there was no change in the mRNA level of bFGF. This is not unexpected because bFGF -BP apparently does not control the expression of bFGF, but acts to mobilize it from the ECM. Therefore, down -regulation of bFGF -BP may not change the level of expression of bFGF, but may result in a decrease in the amount of soluble, active bFGF present. This is supported by the results of a study by O'Brien et al 64 who found no increase in bFGF expression within bladder cancers despite increased urinary levels of bFGF in patients with bladder cancer. 63 Because bFGF -BP, a secreted protein, potentiates the activity of bFGF and, as was demonstrated above, the bFGF -BP levels decline under the influence of p53, one can postulate that down -regulation of bFGF -BP and the resultant antiangiogenic effect could be one factor contributing to a bystander effect in tumors transduced with wtp53. This was evident in the tumors that were injected intratumorally one time with 2Â10 9 pfu of Av1p53 or Av1LacZ4. It was noted that even over the short period of the injection of Av1p53, the tumors regressed significantly (Fig 3) . The small decrease that was observed in the size of the Av1LacZ4 -injected tumors is known to be due to the nonspecific adenoviral LacZ effect, which others have also observed.
The probable role of antiangiogenesis in a p53 gene therapy bystander effect is also suggested by other recent studies. Multiple intravenous injections of a liposome:p53 complex inhibit growth of a malignant human breast cancer cell line implanted into nude mice. 46 However, less than 5% of the tumor was transfected in this system. It was suggested that inhibition of neovascularization could account for the observed inhibition of tumor growth. The close correlation between the antitumor effect of p53 and the reduction of blood vessel density in the tumor suggests that, in the case of breast cancer, p53 effects are mediated, at least in part, by an antiangiogenesis mechanism. 46 Recently, when p53 mutant nonsmall cell lung cancer cells were transduced with Advp53, the expression of the angiogenic factor, VEGF, was dramatically decreased. Simultaneously, increased expression of a novel antiangiogenic factor, brain -specific angiogenesis inhibitor 1, was also observed. 45 This resulted in reduced neovascularization in vivo. Significantly, when mixed with control cells prior to subcutaneous inoculation, tumor cells transduced with the wtp53 gene not only inhibited the in vivo growth of adjacent nontransduced cells, but also resulted in decreased size and number of blood vessels in the ''mixed tumors,'' thus supporting the role of p53's antiangiogenic properties in a bystander effect. 45 A similar conclusion was reached by Rizk et al 70 who observed a weak, but significant, p53-mediated bystander effect in vivo (but not in vitro ) with human mesothelioma xenograft tumors, which they attributed to the antiangiogenic effects of p53. 70 Using xenograft tumors located away from those intratumorally treated with Av1p53, we hoped to establish a role for bFGF -BP in a p53-related bystander effect. But, as evidenced by the expression of wtp53 protein levels in the distant tumors, the down -regulation of bFGF -BP, as well as the growth inhibition observed in these tumors, is most likely in part due to disseminated Av1p53. However, the down -regulation of bFGF -BP expression observed in these tumors is too great to be accounted for solely by the level of Av1p53 available in the blood stream. At most, the circulating Av1p53 could have directly infected 5-10% of the cells in this tumor. 37, 47, 55, 60, 72, 73 To result in the complete elimination of the bFGF -BP signal we observed, every cell, theoretically, must have the gene downregulated. It is conceivable that by regulating the expression of another secreted intermediate (or more than one ), bFGF -BP expression was down -regulated in our system. Although a report by Frank et al 47 suggested that the wtp53 bystander effect observed in SCCHN cells required intracellular contact through a gap junction and did not involve a secreted molecule, it is possible that at least one p53 -regulated intermediate, which may be a secreted molecule, could have participated in intercellular signaling and a bystander effect. Therefore, it is likely that, as is the case with HSV-TK, more than one mechanism is involved in a p53 -mediated bystander effect.
Restoring p53 to SCCHN cells also induces p53-dependent apoptosis in the cells transduced with wtp53. Apoptosis in and of itself could affect neighboring cells by some as yet unknown mechanism( s).
A growing body of evidence gathered from clinical trials also supports the possibility that a bystander effect in p53 gene therapy may contribute to tumor regression in a wide variety of cancers. 71, 72 Wtp53 -mediated tumor growth inhibition is a complex process. These findings have demonstrated that wtp53 -induced tumor regression may be due, at least in part, to antiangiogenesis mediated through the downmodulation of bFGF -BP.
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